Shandong Jincheng Pharmaceutical Group Co., Ltd
300233.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | CN¥3 | CN¥4 | CN¥4 | CN¥3 |
| % Growth | -4.7% | 0.9% | 11.7% | – |
| Cost of Goods Sold | CN¥2 | CN¥2 | CN¥2 | CN¥1 |
| Gross Profit | CN¥1 | CN¥1 | CN¥2 | CN¥2 |
| % Margin | 40.1% | 41.4% | 46.2% | 52.6% |
| R&D Expenses | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| G&A Expenses | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| SG&A Expenses | CN¥1 | CN¥1 | CN¥1 | CN¥1 |
| Sales & Mktg Exp. | CN¥0 | CN¥1 | CN¥1 | CN¥1 |
| Other Operating Expenses | -CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Operating Expenses | CN¥1 | CN¥1 | CN¥1 | CN¥1 |
| Operating Income | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| % Margin | 7.9% | 6.4% | 10.1% | 6.7% |
| Other Income/Exp. Net | CN¥0 | -CN¥0 | -CN¥0 | -CN¥0 |
| Pre-Tax Income | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Tax Expense | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Net Income | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| % Margin | 5.8% | 4.9% | 7.8% | 3.4% |
| EPS | 0.52 | 0.46 | 0.71 | 0.28 |
| % Growth | 13% | -35.2% | 153.6% | – |
| EPS Diluted | 0.52 | 0.46 | 0.71 | 0.28 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Interest Expense | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Depreciation & Amortization | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| EBITDA | CN¥1 | CN¥1 | CN¥1 | CN¥0 |
| % Margin | 18% | 15.9% | 17.9% | 14.3% |